Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
Kageaki TaimaHisashi TanakaYoshihito TanakaMasamichi ItogaShingo TakanashiSadatomo Tasaka
Author information
JOURNALS OPEN ACCESS

2017 Volume 56 Issue 17 Pages 2321-2324

Details
Abstract

Crizotinib, which is effective in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer, is sometimes associated with the generation of complex renal cysts. A 56-year-old man with ALK positive adenocarcinoma received crizotinib. Ten months after the introduction of crizotinib, a cystic lesion developed from his right kidney to the iliopsoas muscle, accompanied by fever, anemia, and hypoproteinemia. After 17 months of treatment, crizotinib was switched to alectinib, followed by the recovery of hypoproteinemia and systemic inflammation. Switching to alectinib may be beneficial in patients demonstrating crizotinib-associated complex renal cysts with systemic inflammation and exhaustion.

Information related to the author
© 2017 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top